Table 2.

Landmark clinical trials in the development of monoclonal antibodies targeting EGFR

Drug Name	Clinical Trial ID	Trial Name	Population	Comparator	Year	Sponsor	Phase	N	Median OS (months)	Median PFS (months)
Monoclonal antibodies to EGFR
Cetuximab (Erbitux®)
Cetuximab (400 mg/m2 initial + 250 mg/m2/week) + cisplatin + vinorelbine	NCT00148798	FLEX	NSCLC	Cisplatin + vinorelbine	2005–2014	Merck KGaA	III	1861	11.3 vs 10.1	4.8 vs 4.8
Cetuximab (400 mg/m2 initial + 250 mg/m2/week)	NCT01001377	ASPECCT	Metastatic CRC	Panitumumab	2010–2017	Amgen	III	1010	10.0 vs 10.4	4.4 vs 4.1
Cetuximab [400/250 mg/m2 (initial/weekly)] + Chemotherapy	NCT00122460	EXTREME	H&N Cancer	Chemotherapy	2004–2011	Merck KGaA	III	442	10.1 vs 7.4	5.6 vs 3.3
Cetuximab [400/200 mg/m2 (initial/weekly)] + FOLFIRI	NCT00154102	CRYSTAL	Metastatic CRC (KRAS WT)	FOLFIRI	2004–2011	Merck KGaA	III	1221	23.5 vs 20.0	9.9 vs 8.4
Cetuximab + 5-FU/FA + oxaliplatin (FOLFOX-4)	NCT00125034	OPUS	Metastatic CRC (KRAS WT)	5-FU/FA + oxaliplatin	2005–2010	Merck KGaA	II	344	22.8 vs 18.5	8.3 vs 7.2
Panitumumab (Vectibix®)
Panitumumab (6 mg/kg/2w) + FOLFOX	NCT00364013	PRIME	Metastatic CRC (WT KRAS)	FOLFOX	2006–2013	Amgen	III	1183	23.9 vs 19.7	9.6 vs 8.0
Panitumumab (6 mg/kg/2w) + FOLFOX	NCT00364013	PRIME	Metastatic CRC (Mutant KRAS)	FOLFOX	2006–2013	Amgen	III	1183	15.5 vs 19.3	7.3 vs 8.8
Panitumumab (6 mg/kg/2w) + BSC	NCT01412957	‘0007	Metastatic CRC (WT RAS)	BSC	2011–2017	Amgen	III	377	10.0 vs 6.9	5.2 vs 1.7
Necitumumab (Portrazza®)
Necitumumab (800 mg/ m2/3w) + gemcitabine + cisplatin	NCT00981058	SQUIRE	NSCLC	Gemcitabine + cisplatin	2010–2018	Eli Lilly and Company	III	1093	11.5 vs 9.9	5.7 vs 5.5
Necitumumab (500 mg/m2/3w) + Chemotherapy	NCT00982111	INSPIRE	NSCLC	Chemotherapy	2009–2018	Eli Lilly and Company	III	633	11.3 vs 11.5	5.6 vs 5.6